Abstract
ABSTRACT
Regulatory and scientific aspects of the proposed replacement chlorofluorocarbons (CFCs) in medicinal products are discussed. Preclinical toxicity studies as well as clinical safety and effectiveness studies are needed for an adequate assessment of the new propellants used in drug products.
Get full access to this article
View all access options for this article.